Palmar-plantar erythrodysaesthesia associated with an initial course of bolus fluorouracil [6]

Journal of Pharmacy Practice and Research

Volumn 32, Issue 3, 2002, Pages 178-179

  Gilbar, Peter ^a  

^a Toowoomba Health Services   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; OPIATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; BOLUS INJECTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CASE REPORT; CLINICAL FEATURE; DRUG INFUSION; ENZYME DEFICIENCY; FEMALE; HAND FOOT SYNDROME; HUMAN; LETTER; NAUSEA;

EID: 0036760923     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr2002323178a     Document Type: Letter

References (9)

1. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24: 457-61.
2. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-800.
3. Meta-Analysis Group in Cancer, Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-41.
4. Atkins JN. Fluorouracil and the palmar-plantar erythrodysesthesia syndrome [letter] Ann Intern Med 1985; 102: 419.
5. Curran CF, Luce JK. Fluorouracil and palmar-plantar erythrodysesthesia. [letter] Ann Intern Med 1989; 111: 858.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
7. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-37.
8. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implications for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4: 325-9.
9. Diasio RB, Johnson MR, Dihydropyrimidine dehydrogenase: Its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5: 2672-3.